Literature DB >> 10229437

Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments.

D van der Heijde1, S van der Linden, M Dougados, N Bellamy, A S Russell, J Edmonds.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10229437

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  14 in total

1.  [Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area].

Authors:  J Braun; J Zochling; E Märker-Hermann; G Stucki; H Böhm; M Rudwaleit; H Zeidler; J Sieper
Journal:  Z Rheumatol       Date:  2006-12       Impact factor: 1.372

Review 2.  ASessment in Ankylosing Spondylitis (ASAS) international working group: a model for psoriatic arthritis and psoriasis?

Authors:  D van der Heijde; J Braun; R Landewé; J Davis; J Sieper; S van der Linden; M Dougados
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

3.  ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; R Burgos-Vargas; E Collantes; J C Davis; B Dijkmans; M Dougados; P Géher; R D Inman; M A Khan; T K Kvien; M Leirisalo-Repo; I Olivieri; K Pavelka; J Sieper; G Stucki; R D Sturrock; S van der Linden; D Wendling; H Böhm; B J van Royen; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

4.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8 Therapy, 8.1 Treatment concept, 8.2 Therapy targets and strategy].

Authors:  U Kiltz; J Sieper; M Rudwaleit; H Kellner; D Krause; E Böhle; H Böhm; W-H Böhncke; J-F Chenot; A Heiligenhaus; S Jaresch; W Mau; U Oberschelp; U Pleyer; U Repschläger; E Schneider; U Smolenski; A Stallmach; M Stemmer; B Swoboda; C Ulrich; M Winking; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

5.  Doppler enthesitis: a potential useful outcome in the assessment of axial spondyloarthritis and psoriatic arthritis.

Authors:  Juan Molina Collada; Cristina Macía-Villa; Chamaida Plasencia; José María Álvaro-Gracia; Eugenio de Miguel
Journal:  Clin Rheumatol       Date:  2020-10-09       Impact factor: 2.980

Review 6.  Minimal disease activity in axial spondyloarthritis: the need of the hour and a proposal for development.

Authors:  Atul A Deodhar; Anand Kumthekar; Maureen Dubreuil
Journal:  Curr Opin Rheumatol       Date:  2017-07       Impact factor: 5.006

Review 7.  New directions in classification and outcome assessment in ankylosing spondylitis.

Authors:  Désirée van der Heijde
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

8.  Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group.

Authors:  T Pham; D van der Heijde; A Calin; M A Khan; Sj van der Linden; N Bellamy; M Dougados
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

9.  An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis.

Authors:  T Pham; R Landewé; S van der Linden; M Dougados; J Sieper; J Braun; J Davis; M Rudwaleit; E Collantes; R Burgos-Vargas; J Edmonds; I Olivieri; I van der Horst-Bruinsma; H Mielants; M Stone; P Emery; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2006-02-07       Impact factor: 19.103

10.  [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Authors:  U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.